Copper(II) interacting with the non-steroidal antiinflammatory drug flufenamic acid: Structure, antioxidant activity and binding to DNA and albumins

Copper(II) complexes with the non-steroidal anti-inflammatory drug tolfenamic acid: Structure and biological features

“…Similar bands have been reported for the Cu(II) complexes with the NSAIDs mefenamic acid, diflunisal, naproxen and diclofenac [5][6][7]24]. Fig.…”

“…Furthermore, complexes 1-6 exhibit higher DPPH, similar hydroxyl and lower ABTS scavenging activity in comparison to the Zn(II)-tolfenamato analogues [15], while the LOX inhibitory activity is of the same magnitude. The DPPH and hydroxyl scavenging activity of complexes 1-6 is higher than their naproxenato, mefenamato and flufenamato copper(II) analogues [5,7,47], in contrast to their ABTS scavenging activity which is lower. Additionally, the LOX inhibition activity of complexes 1-6 is among the highest found in comparison to their copper(II) mefenamato and flufenamato analogues [5,47].…”

“…The complex [Cu 2 (indo) 4 (DMF) 2 ] (Hindo is the non-steroidal anti-inflammatory drug (NSAID) indomethacin and DMF = N,N-dimethylformamide) is already used as anti-inflammatory medication and diverse copper compounds have been applied in the treatment of arthritis and as antimicrobial agents [2,3]. As a result of the synergetic activity with drugs, a series of Cu(II) complexes have also exhibited noteworthy antitumor [4], antioxidant [5][6][7], bactericidal [8] and fungicidal [9] activity in the attempt of the researchers to obtain novel effective metallodrugs.…”

Biophysical study on the interaction between two palladium(II) complexes and human serum albumin by Multispectroscopic methods

“…The results show that complex II has a higher binding constant value compared to complex I implying a relatively strong association to HSA. Also, the values of K b for the above complexes are much higher than those of metal complexes reported earlier, which reflected better interaction probability of these complexes compared to other therapeutic agents [34][35][36].The number of binding sites (n) was approximately equal to 1, indicating that there was one site for the binding of Pd(II) complexes to HSA molecule [37].…”

Electrochemical, spectroscopic, and theoretical studies on the interaction between azathioprine and DNA

“…The diffusion-control behavior was evident from the linear plot of the voltammetric response as a function of ν 1/2 . From the slope of the obtained line, diffusion coefficient for free AZT (D f ) was calculated as 5.86× 10 -5 cm 2 s -1 , whereas for the AZT-DNA complex, D b was reduced to 2.90 × 10 -5 cm 2 s -1 .The negative shift in potential of C 1 during successive additions of DNA, confirms the nonintercalative nature of the interaction, indeed it refers to electrostatic interactions with DNA[21,[25][26][27][28].…”